- Home
- QGEN vs RVMD Comparison
QGEN vs RVMD Comparison
Compare QGEN & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- RVMD
- Stock Information
- Founded
- QGEN 1986
- RVMD 2014
- Country
- QGEN Netherlands
- RVMD United States
- Employees
- QGEN N/A
- RVMD N/A
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QGEN Health Care
- RVMD Health Care
- Exchange
- QGEN Nasdaq
- RVMD Nasdaq
- Market Cap
- QGEN 9.7B
- RVMD 10.2B
- IPO Year
- QGEN 1996
- RVMD 2020
- Fundamental
- Price
- QGEN $42.78
- RVMD $56.75
- Analyst Decision
- QGEN Buy
- RVMD Strong Buy
- Analyst Count
- QGEN 9
- RVMD 12
- Target Price
- QGEN $51.05
- RVMD $59.25
- AVG Volume (30 Days)
- QGEN 981.6K
- RVMD 1.5M
- Earning Date
- QGEN 11-06-2024
- RVMD 11-06-2024
- Dividend Yield
- QGEN 3.09%
- RVMD N/A
- EPS Growth
- QGEN N/A
- RVMD N/A
- EPS
- QGEN 0.41
- RVMD N/A
- Revenue
- QGEN $1,966,174,000.00
- RVMD $742,000.00
- Revenue This Year
- QGEN $2.68
- RVMD N/A
- Revenue Next Year
- QGEN $5.95
- RVMD $300.00
- P/E Ratio
- QGEN $103.18
- RVMD N/A
- Revenue Growth
- QGEN 0.62
- RVMD N/A
- 52 Week Low
- QGEN $39.03
- RVMD $20.98
- 52 Week High
- QGEN $47.44
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- QGEN 50.48
- RVMD 58.35
- Support Level
- QGEN $40.35
- RVMD $53.69
- Resistance Level
- QGEN $42.86
- RVMD $58.83
- Average True Range (ATR)
- QGEN 0.83
- RVMD 2.11
- MACD
- QGEN -0.01
- RVMD -0.44
- Stochastic Oscillator
- QGEN 48.50
- RVMD 35.13
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.